About HRTIS

Founded: 2008
Employees: 14
CEO: Antti Vuolanto
WebsiteView website: herantis.com

Herantis Pharma Oyj, a clinical stage biotechnology company, engages in the development of disease-modifying cerebral dopamine neurotrophic factor (CDNF) based therapies for Parkinson’s disease (PD). The company’s lead product in pipeline includes HER-096, an advanced small synthetic chemical peptidomimetic molecule developed based on the active site of the CDNF protein that is in phase 1b clinical trial for the treatment of PD and other neurodegenerative diseases. Herantis Pharma Oyj was incorporated in 2008 and is based in Espoo, Finland.

Recent HRTIS News & Updates

New Risk • Aug 14

New major risk - Share price stability

The company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Finnish stocks, typically moving 7.6% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (7.6% average weekly change). Negative equity (-€1.7m). Earnings are forecast to decline by an average of 9.5% per year for the foreseeable future. Revenue is less than US$1m. Minor Risks Currently unprofitable and not forecast to become profitable over next 3 years (€8.4m net loss in 3 years). Market cap is less than US$100m (€46.6m market cap, or US$53.9m).

Recent updates

No updates

Herantis Pharma Oyj Stock Price

HRTIS Share Price Performance

HRTIS Community Narratives

Trending Discussion

Recently Updated Narratives

Snowflake Analysis

Herantis Pharma Oyj Key Details

About HRTIS

Recent HRTIS News & Updates

We're Not Very Worried About Herantis Pharma Oyj's (HEL:HRTIS) Cash Burn Rate

New major risk - Financial position

New major risk - Share price stability

Recent updates

Herantis Pharma Oyj Competitors

Nanoform Finland Oyj